On Feb. 27, 2020, a consortium of philanthropic, non-profit and private sector organisations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that were ready for phase 3 development.

The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment.